tradingkey.logo

BUZZ-Axsome declines after mixed data from Alzheimer's-related drug

ReutersDec 30, 2024 12:44 PM

** Shares of Axsome Therapeutics AXSM.O fall 8.2% to $79.60 premarket

** AXSM says its experimental drug failed to meet the main goal in one of two late-stage studies in patients with Alzheimer's disease related agitation

** The drug, AXS-05, did not show statistically significant improvement in delaying relapse time of agitation in patients compared to placebo

** However, AXSM said the results "numerically favoured" the drug over placebo across main and secondary goals

** In the other study, AXS-05 helped delay relapse time in patients compared to placebo

** Agitation is a symptom that causes emotional distress as well as verbal and physical aggressiveness

** Co plans to submit its marketing application to U.S. FDA in H2 2025

** As of last close, stock has risen ~9% since December 2023

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI